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Alcohol-related brain injury (ARBI) is an unrecognised and therefore untreated consequence of 
alcohol use disorder. Here, we explore 12-month period prevalence of alcohol-related brain injury 
(ARBI) in alcohol use disorder patients. Inpatients aged ≥18 years reviewed by the Alcohol Care 
Team’s Specialist Nurses between 1 April 2017 and 31 March 2018 were eligible for the study 
(n=1276). Screening identified a high-risk subset of patients who matched at least one of the 
following: 1) more than three alcohol-related admissions in one year; 2) two alcohol related 
admissions in any given 30-day period; 3) patient or their significant other had concerns regarding 
cognition. The high-risk patients were assessed for evidence of ARBI using the Montreal Cognitive 
Assessment Tool (MoCA). The primary measure of interest was MoCA ≤23. Analysis was conducted 
between subgroups of the study population to identify prevalence rate ratios for matching the high-
risk screening criteria, and MoCA ≤23 in high-risk patients. 205 patients were identified as high risk 
for ARBI. The period prevalence rates in this high-risk group for patients with a MoCA ≤23 was 
36.1%. Those under the age of 35 years were significantly less likely to match the high-risk criteria. 
Patients staying in hostels or homeless were more likely to match the high-risk criteria and were also 
at increased risk of MoCA ≤23 compared with those living with family members. In summary, ARBI is 
common in patients with AUD attending acute hospitals. ARBI is often not diagnosed, and thus 
further work is required to improve screening for, and identification of, these patients to develop 
evidence-based clinical pathways which optimise care.   








• Through stratification, 205 patients were classified at increased risk of ARBI. 
• We estimated the period prevalence of ARBI in this high-risk group to be 36.1%. 





















The effects of excessive and prolonged alcohol consumption on the brain are well-recognised, but 
not completely understood (Abrahao, Salinas, & Lovinger, 2017). A systematic review of brain injury 
identified neurodegenerative changes in heavy drinkers, but also highlighted the potential for 
reversibility with sustained abstinence (Bühler & Mann, 2011). Alcohol Related Brain Injury (ARBI) is 
an umbrella term for a number of neurodegenerative complications caused by heavy drinking.  
Features of ARBI include executive dysfunction and behavioural changes (Saxton, Munro, Butters, 
Schramke, & McNeil, 2000), but there are no internationally agreed standardised criteria for 
determining the presence of ARBI, which is further confounded by  variation in the terms used to 
describe the condition; these include ‘alcohol-related brain damage’, ‘alcohol-related dementia’ and 
‘alcoholic amnesia syndrome’.  ARBI is used in this manuscript to describe cognitive impairment in 
the absence of other conditions known to affect cognition such as Wernicke’s or hepatic 
encephalopathy.  
 
ARBI typically leads to a vortex of physical and psychological harms often necessitating hospital 
admission, and creating distress for the patient and their families (Wilson et al., 2012).  Detection of 
ARBI in alcohol use disorder (AUD) patients at the earliest opportunity is therefore important in 
facilitating more appropriate, patient-centred care.  However, because ARBI is generally 
unrecognised and therefore untreated, it is unknown how many patients with ARBI attend alcohol 
treatment services.  Furthermore, lack of recognition of ARBI may lead to the patient being 
erroneously labelled as ‘non-compliant’ or ‘problematic’ due to their diminished ability to 




Given the gaps in knowledge and clinical resources for recognising and managing the ARBI 
population, we have used the Montréal Cognitive Assessment Tool (MoCA) tool to identify ARBI in 
AUD patients attending an acute inner city hospital over a 12-month period, with a score below cut-
off considered as potential evidence of underlying ARBI (Angermann et al., 2017; Ball, Carrington, 
Stewart, & investigators, 2013; Carson, Leach, & Murphy, 2018; Luis, Keegan, & Mullan, 2009). 
MoCA is a brief cognitive screening instrument (Nasreddine et al., 2005) that has been used in 
different clinical settings because of its high sensitivity and specificity, and test–retest reliability of 
0.92, for detecting cognitive-related defects (Copersino et al., 2009; Luis et al., 2009; Popović, Šerić, 
& Demarin, 2007). A considerable body of evidence suggests that the MoCA is superior to the Mini-
Mental State Examination (MMSE), in detecting cognitive impairment (Hoops et al., 2009; Popović et 
al., 2007). Specifically, the MoCA assesses the following cognitive domains: visual-spatial abilities; 
executive function; language and phonemic fluency; verbal abstraction; short-term memory recall; 
attention; concentration; working memory; and orientation. It can be administered within 10 
minutes and cut-off scores are used for detecting and categorising impairment. The specific aims of 
our study were to: i) explore 12-month period prevalence of ARBI in AUD patients; and ii) define if 
these rates are influenced by patient characteristics and/or behaviour.   
 
MATERIAL AND METHODS 
Study population and data collection 
Data for this cohort study was sourced from an acute hospital in the UK, which serves a local 
population of approximately 465,000. The study population consisted of all inpatients aged 18 years 
and over who were reviewed by the Alcohol Care Team’s Specialist Nurses (ASN) between 1 April 
2017 and 31 March 2018. A retrospective dataset was completed by an independent administrator 
using patient case notes and hospital electronic information systems. Data included demographics, 
Alcohol Use Disorders Identification Test (AUDIT) (Babor, Higgins-Biddle, Saunders, & Monteiro, 
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2001), Severity of alcohol dependence questionnaire (SADQ) score (Stockwell, Hodgson, Edwards, 
Taylor, & Rankin, 1979), postcode data for calculating index of multiple deprivation (IMD) outcomes, 
and smoking. Access to the data for this project was granted by the Royal Liverpool University 
Hospital NHS Trust Official Trust Audit Board (ID: A03301). 
 
MoCA screening 
As part of a review by the ASN, each patient matching at least one the following was considered high 
risk and assessed for evidence of ARBI using the MoCA tool: 1) More than three alcohol-related 
admissions in one year; 2) Two alcohol related admissions in any given 30-day period; and 3) Patient 
or their significant other had concerns regarding cognition. Patients were not screened with MoCA if 
they had a breath alcohol content >0, co-morbid neurological or psychiatric diseases that might 
explain impaired cognition (e.g. hepatic encephalopathy, previous known stroke/TIA, dementia, 
Alzheimer’s disease), cannabis or other illicit drug use in previous 48 hours, or prescribed any 
sedative in previous 48 hours. The primary measure of interest was MoCA ≤23, which triggered a 
referral to psychiatric liaison for further assessment. Utilisation of this cut-off was based on evidence 
of optimal diagnostic accuracy from previous work (Angermann et al., 2017; Ball et al., 2013; Carson 
et al., 2018; Luis et al., 2009).  
 
Data Analysis 
The period prevalence rate of MoCa ≤23 was estimated for the high-risk subset of patients (“high 
risk cohort”). Sensitivity analysis was performed to investigate period prevalence using cut-offs 
proposed in other condition-specific research of ≤21 (Salvadori et al., 2013) and ≤25 (Copersino et 
al., 2009; Nasreddine et al., 2005). The prevalence of patients in the whole cohort who met at least 




Relative rates of MoCA ≤23 in the high-risk cohort were estimated in univariable analysis stratified 
by gender, age bands, individual-level IMD 2015 quintiles, and smoking status. The IMD scores were 
skewed towards higher deprivation, and therefore the quintiles presented are based on within study 
bounds and are not representative of population-level cut-offs. Standardised rates were calculated 
for each measure using the stratum-specific proportions from the high-risk cohort. Formal analysis 
was undertaken using prevalence rate ratios, presented with 95% confidence intervals. A reference 
group was selected for each variable and null hypothesis testing conducted based on a rate ratio 
equal to 1. Statistical significance was set at P<0.05. All data analysis was conducted using R (version 
3.2.5) and the R package ‘fmsb’.  
 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were 
utilised, where applicable.  
 
RESULTS 
Cohort and period prevalence of ARBI 
The entire cohort consisted of 1276 patients. Average age was 52 years (SD=14) and 885 (69.4%) 
were males. The mean AUDIT and SADQ scores were 20.8 (SD=8.7) and 19.3 (SD=9.9), respectively. 
The most common type of alcohol consumed was spirits (n=469; 36.8% of patients). Four-hundred 
and fifty-four were current smokers (35.6%). The 12-month period prevalence for matching at least 
one of the criteria for high risk of ARBI was 16.1% (n=205; ‘high risk cohort’). The prevalence of 
MoCA ≤23 in this high group was 36.1%; which is equal to 5.8% of the entire cohort, although not all 
patients were assessed with MoCA meaning this figure cannot be fully validated. The estimated rate 
for the high-risk group was 26.3% when the MoCA cut-off was adjusted to ≤21, and 53.7% when 




Variables associated with matching high risk criteria 
Table 1 presents rates of patients matching one or more of the high-risk criteria, which resulted in 
MoCA assessment. The standardised rate for females and males was 15.9 and 16.2 per 100 patients, 
respectively, which was not significantly different ([prevalence rate ratio] 1.02; 95%CI: 0.78-1.34). 
Those under the age of 35 years were significantly less likely (0.51; 95%CI: 0.29-0.92) to match the 
‘high risk’ criteria than the reference group (i.e. 35-44 years); all other age bands had similar rates. 
There was suggestion of a deprivation gradient, such that those from more deprived areas were at 
greater risk; although the only outcome that reached significance was between the least deprived 
and second most deprived quintiles (1.73; 95%CI: 1.15-2.59). Living in a family environment 
appeared to be a protective factor, with those staying in a hostel (4.68; 95%CI: 2.37-9.24) or being 
homeless (1.91; 95%CI: 1.02-3.59) having rates that were >1.5-fold higher than those of the 
reference group. None of the other investigated variables showed significant differences. 
 
Variables associated with MoCA ≤23 in the high-risk cohort 
Table 2 presents prevalence rate ratios of patients with a MoCA score ≤23 from the high-risk cohort. 
The standardised rate for females and males was 41.9 and 33.6 per 100 patients, respectively (0.80; 
95%CI: 0.55-1.16). None of the investigated variables showed significant differences, likely due to a 
lack of power or screening processes resulting in a homogenous high-risk group.  
 
Multivariate analysis was not conducted given the limited statistical rationale for such an approach 





This study provides an estimate of ARBI in an acute care setting in the UK. We found that 16.1% of all 
inpatients seen by the ACT team were at increased risk of ARBI and 36.1% of this high-risk group 
screened positive for potential ARBI, with a MoCA score of ≤23.  These findings offer insight into the 
size of this poorly defined clinical entity, and provide approximate baseline metrics on which to 
assess changes over time.   
 
Identifying ARBI in acute care settings is important given that traditional approaches to alcohol 
treatment are entirely reliant on the patients’ ability to retain and understand messages. Although 
generalist healthcare professionals are becoming more aware of the burden associated with the 
consequences of ARBI, there exists no standard guidance in an acute hospital setting on how to 
identify the presence or stratify severity of ARBI. Therefore, failure to detect the presence of ARBI 
results in patients being expected to comply with care pathways that they neither understand nor 
remember (Bates, Buckman, & Nguyen, 2013). Consequently, alternative approaches to care need to 
be designed to account for and manage the associated cognitive defects. These need to include: a) 
clear stratification of risk factors b) identification through routine screening of patients at risk, c) 
greater involvement of family and other carers, d) consideration of pharmacotherapy to reduce 
cravings, and e) close monitoring of co-morbidities. However, there needs to be further work to 
develop an agreed phenotypic definition of ARBI which will help better define the scale of the 
problem and improve clinical pathways. 
 
The most commonly used clinical definition of ARBI is given in the Diagnostic and Statistical Manual 
Version IV (Frances, 1994); however this has been shown to be vague and subjective with poor utility 
in acute care settings (Oslin, Atkinson, Smith, & Hendrie, 1998). Oslin and colleagues attempted to 
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anchor the diagnosis based on duration and volume of alcohol consumption (Oslin et al., 1998), but 
there has been limited uptake of this definition in both clinical and research environments. Indeed, 
rates of ARBI in different studies have been variable (Cheng et al., 2017). For example, a 0.001% 
prevalence has been estimated in a general population of 300,000 based on an adapted version of 
the Oslin criteria (Wilson et al., 2012).  By contrast, 25.6% of 39 institutionalised AUD patients had 
ARBI diagnosed using a battery of cognitive tests (cognitive deficit was defined as performance at 
least 1.5 SD below the normal control mean for MMSE, NART-R, CERAD, Trailmaking Test and/or 
Clock drawing) (Saxton et al., 2000). A study of homeless hostel dwellers in Glasgow reported that 
21% had evidence of ARBI, defined using a cut-off of <88 on the Addenbrooke's Cognitive 
Examination alongside positive screens on several alcohol consumption questionnaires (Gilchrist & 
Morrison, 2005). There are no studies providing a directly comparable estimate of the prevalence of 
ARBI in an acute care setting, which highlights the dearth of research and associated knowledge gap 
for this condition. 
 
The MoCA offers an alternative approach to early screening of neurodegenerative changes, and has 
been shown to be a viable tool in patients with AUD (Alarcon, Nalpas, Pelletier, & Perney, 2015). The 
MoCA has also been shown to be sensitive to changes in cognitive performance over time in patients 
with AUD (Pelletier, Nalpas, Alarcon, Rigole, & Perney, 2016), which adds to its clinical value. A 
recent study of 90 AUD patients also demonstrated the superiority of MoCA over the Brief 
Evaluation of Alcohol-Related Neuropsychological Impairments (i.e. BEARNI) in detecting cognitive 
impairment (Pelletier et al., 2018). MoCA scores of 23.6 and 21.8 were found to detect mild and 
moderate to severe dysfunction respectively against a standardised assessment, and the tool had a 
sensitivity of 0.79 and specificity of 0.65 for characterising patients. The sensitivity and specificity of 
MoCA for detection of ARBI still needs to be determined but is problematic given the lack of 
consensus on the most robust diagnostic (i.e. gold standard) criteria. When considering the 
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performance of MoCA across other conditions, the MMSE is often used as a comparator. The MoCA 
has been shown to outperform MMSE for detection of mild cognitive impairment in Parkinson’s 
disease (Hoops et al., 2009), post-stroke vascular cognitive impairment (Dong et al., 2010), and 
transient ischemic attack (Pendlebury et al., 2012). Whether MoCA or MSSE is superior in the 
current population and context is yet to be tested. 
 
There was minimal support for evidence of ARBI risk factors based on patient characteristics or 
behaviour. This is likely a reflection of the limited sample size which resulted in low power to detect 
differences once the groups were categorised. However, patients who were homeless or living in 
hostels were more likely to be screened as high risk and therefore assessed using MoCA, and there 
was trend towards a greater risk of ARBI in these subgroups (i.e. MoCA ≤23). This could be due to 
several interacting factors, including lack of support and/or poor nutrition. Nutritional deficiencies, 
especially low thiamine, increase the risk of ARBI susceptibility (Lovinger, 1993). For example, Lee 
and colleagues have shown that AUD individuals with nutritional deficiencies are at augmented risk 
of corpus callosum shrinkage (Lee, Jung, Na, Park, & Kim, 2005). Further investigation regarding the 
contribution of macro and micro nutrients to ARBI is required.          
 
This study has highlighted that ARBI is likely to be common in acute settings. But it also highlights the 
need for larger studies that build on a consensus definition and moves toward randomised 
controlled trials that can test interventions.  It is important that the link we have identified between 
the positive MoCA screen and ARBI risk is formally validated. The criteria against which the MoCA 
and other tools are assessed needs to be carefully considered given the aforementioned lack of 
consensus in diagnostic criteria. Our sensitivity analysis of MoCA cut-offs revealed variation in 
prevalence estimates, suggesting the need for further conclusive work in this area.  Furthermore, 
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although some studies have shown that MoCA is superior than other tools, there are still gaps in the 
literature regarding which tool is most appropriate for this patient group.  
 
A limitation of our study is that we were only able to calculate the period prevalence. As this 
pathway was newly implemented, we were unable to determine how many cases were new vs. 
existing, precluding the calculation of incidence. Furthermore, there might be an issue relating to 
inflation as frequent attenders will have been captured in this cohort and new entrants into the 
cohort might be rarer. Additionally, the study population in terms of IMD diversity was extremely 
homogenous. This precluded accurate assessment of ARBI risk by social status, but it again highlights 
the clustering of treatment need for AUD in less advantaged areas (Bellis et al., 2016).  
 
In conclusion, our study which has assessed the prevalence of potential ARBI in AUD patients in an 
acute setting is important as it highlights a hidden problem in a patient population that is 
underrepresented and often misunderstood in terms of clinical care. There is a need to increase 
clinical awareness of ARBI alongside building skills and competence in the workforce to ensure 
provision of appropriate patient-centred care. We acknowledge that this is the first important step 
in a process and that further work is required to a) develop consensus criteria for the diagnosis of 
ARBI, b) fully validate the MoCA for the assessment of ARBI, c) understand its utility in this setting, 
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Table 1: Variables predicting patients matching MoCA screening criteria 
   
Rate/100  
patients  
Risk ratio  
(95% CI) 
P-value 
Gender:      
 Female   15.9 - -  
 Male   16.2 1.02 (0.78,1.34) 0.893 
Age:      
 <35   8.7 0.51 (0.29,0.92) 0.020 
 35-44   17.0 - -  
 45-54   18.2 1.07 (0.75,1.52) 0.711 
 55-64   16.7 0.98 (0.67,1.44) 0.931 
 ≥65  15.7 0.92 (0.61,1.38) 0.694 
Within study 
Deprivation: 
    
 
  5 (least)   12.6 - -  
 4  14.6 1.15 (0.74,1.80) 0.535 
 3  16.2 1.97 (0.83,1.98) 0.264 
 2  21.9 1.73 (1.15,2.59) 0.007 
 1 (most)  15.8 1.25 (0.81,1.93) 0.320 
Smoker:      
  No  13.9 - -  
  Yes   16.7 1.21 (0.90,1.63) 0.216 
Living environment:      
  Family   13.7 - -  
 Alone  15.4 1.13 (0.79,1.59) 0.505 
 Homeless  23.7 1.91 (1.02,3.59) 0.050 
 Hostel  22.4 4.68 (2.37,9.24) <0.0005 
 Supported  17.5 1.41 (0.69,2.91) 0.356 
17 
 
AUDIT:      
  Low   14.5 - -  
 Increasing  9.2 0.63 (0.34,1.71) 0.143 
 High  17.9 1.23 (0.79,1.91) 0.343 




 15.6 - - 
 
 
 High ABV beer/cider  20.1 1.29 (0.87,1.90) 0.202 
 Spirits  14.9 0.96 (0.69,1.33) 0.796 
 Wine  17.3 1.11 (0.71,1.73) 0.650 
Table 2: Variables associated with MoCA ≤23 in high risk cohort (n=205) 
   
Rate/100  
patients  
Risk ratio  
(95% CI) 
P-value 
Gender:      
 Female   41.9 - -  
 Male   33.6 0.80 (0.55,1.16) 0.253 
Age:      
 <35   7.7 0.24 (0.04,1.68) 0.088 
 35-44   31.7 - -  
 45-54   33.8 1.07 (0.61,1.87) 0.821 
 55-64   41.3 1.30 (0.74,2.30) 0.357 
 ≥65  48.6 1.53 (0.88,2.68) 0.129 
Within study 
Deprivation: 
    
 
  5 (least)   41.9 - -  
 4  38.9 0.93 (0.52,1.66) 0.801 
 3  30.0 0.71 (0.38,1.34) 0.300 
 2  35.2 0.84 (0.48,1.45) 0.539 
 1 (most)  35.9 0.86 (0.47,1.54) 0.609 
Smoker:      
  No  34.3 - -  
  Yes   35.5 1.04 (0.66,1.61) 0.876 
AUDIT:      
  Low   31.6 - -  
 Increasing  23.5 0.75 (0.25,2.20) 0.596 
 High  38.7 1.23 (0.61,2.45) 0.547 
 
HIGHLIGHTS 
• Through stratification, 205 patients were classified at increased risk of ARBI. 
• We estimated the period prevalence of ARBI in this high-risk group to be 36.1%. 
• Factors associated with ARBI development and progression remain knowledge gaps.  
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